These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 32643550)

  • 1. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
    Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
    J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Al-Sehemi AG; Parulekar RS; Pannipara M; P P MA; Zubaidha PK; Bhatia MS; Mohanta TK; Al-Harrasi A
    J Biomol Struct Dyn; 2023 Jan; 41(1):280-297. PubMed ID: 34809523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
    Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
    J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
    Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
    J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M
    Purohit P; Dash JJ; Muya JT; Meher BR
    J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyanobacterial metabolites as promising drug leads against the M
    Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A
    J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
    Majumder R; Mandal M
    J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withanone and caffeic acid phenethyl ester are predicted to interact with main protease (M
    Kumar V; Dhanjal JK; Kaul SC; Wadhwa R; Sundar D
    J Biomol Struct Dyn; 2021 Jul; 39(11):3842-3854. PubMed ID: 32431217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (M
    Das P; Majumder R; Mandal M; Basak P
    J Biomol Struct Dyn; 2021 Oct; 39(16):6265-6280. PubMed ID: 32705952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural-like products as potential SARS-CoV-2 M
    Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Hegazy MF
    J Biomol Struct Dyn; 2021 Sep; 39(15):5722-5734. PubMed ID: 32643529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes.
    Li M; Liu X; Zhang S; Liang S; Zhang Q; Chen J
    Phys Chem Chem Phys; 2022 Sep; 24(36):22129-22143. PubMed ID: 36082845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
    Avti P; Chauhan A; Shekhar N; Prajapat M; Sarma P; Kaur H; Bhattacharyya A; Kumar S; Prakash A; Sharma S; Medhi B
    J Biomol Struct Dyn; 2022; 40(19):8894-8904. PubMed ID: 33998950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening and structure-based 3D pharmacophore approach to identify small-molecule inhibitors of SARS-CoV-2 M
    Elseginy SA
    J Biomol Struct Dyn; 2022; 40(24):13658-13674. PubMed ID: 34676801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A computational study on active constituents of
    Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A
    J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.